Association of NETs Markers with Clinical and Radiological Outcomes in Patients with Acute Ischemic Stroke Undergoing Thrombectomy: Does Heparin Treatment Modify This?
Translational Stroke Research · 2025
DOI: 10.1007/s12975-025-01362-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Translational Stroke Research, 2025. Verfasst von Aarazo Barakzie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Ne…. Hauptthemen laut MEDLINE: Heparin, Ischemic Stroke, Thrombectomy, Extracellular Traps. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium, which is supported by the Netherlands Cardiovascular Research Initiative, an initiative…, the Brain Foundation Netherlands, the Ministry of Economic Affairs by means of the PPP Allowance made available by Top Sector Life Sciences and Health to stimulate public-private partnerships.
Themen: Schlaganfall
Abstract (Originalsprache)
The aim of this study is to investigate the association of neutrophil extracellular traps (NETs) markers with clinical and radiological outcomes in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) and assess the effect of periprocedural heparin during EVT on NETs markers and their association with outcomes. From 198 AIS patients included in the MRCLEAN-MED trial, randomized to receive EVT with ( N = 104) or without ( N = 94) low-dose unfractionated heparin (5000 IU bolus followed by 500 IU/h for 6 h, n = 104), blood samples were collected at baseline, 1 h, and 24 h post-reperfusion. NETs markers (MPO-DNA, histone-DNA, citrullinated histone H3 [CitH3]) were measured in blood samples, and their associations with stroke severity (National Institutes of Health Stroke Scale [NIHSS] score at 24 h post-reperfusion), long-term functional outcome (modified Rankin Scale [mRS] score at 90-day), and final infarct size (5–7 days) were assessed in EVT and heparin + EVT–treated patients using logistic regression, linear regression, and Pearson’s correlation. Histone-DNA levels at 1 h post-heparin + EVT, but not EVT alone, were positively associated with final infarct size. Histone-DNA levels at 24 h post-heparin + EVT were negatively associated with infarct size mRS and NIHSS, while baseline CitH3 was positively correlated with NIHSS at 24 h post-EVT. Interaction analysis showed that the association between histone-DNA levels at 24 h and NIHSS at 24 h was different in the two treatment groups. No further associations were observed. At 1 h post-heparin + EVT, the histone-DNA levels were independently associated with larger infarct size, while at 24 h, histone-DNA linked to improved outcomes post-heparin + EVT and baseline-CitH3 to worse outcomes post-EVT, suggesting heparin may attenuate histone-DNA’s effect on outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Erasmus MC Cardiovascular Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
- Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Biochemistry, CARIM School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, The Netherlands.
- Thrombosis Expertise Center and Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
Förderung
- Collaboration for New Treatments of Acute Stroke (CONTRAST) consortium, which is supported by the Netherlands Cardiovascular Research Initiative, an initiative…
- the Brain Foundation Netherlands
- the Ministry of Economic Affairs by means of the PPP Allowance made available by Top Sector Life Sciences and Health to stimulate public-private partnerships
- the Ministry of Economic Affairs by means of the PPP Allowance made available by Top Sector Life Sciences and Health to stimulate public–private partnerships
- unrestricted funding by Stryker, Medtronic, and Cerenovus
Zitieren
APA
Barakzie, A., van der Steen, W., Jansen, A. J. G., Roozenbeek, B., Donkel, S. J., van der Lugt, A., Lingsma, H., Dippel, D. W. J., Cate, H. T., de Maat, M. P. M., & CONTRAST consortium (2025). Association of NETs Markers with Clinical and Radiological Outcomes in Patients with Acute Ischemic Stroke Undergoing Thrombectomy: Does Heparin Treatment Modify This?. Translational Stroke Research. https://doi.org/10.1007/s12975-025-01362-0
Vancouver
Barakzie A, van der Steen W, Jansen AJG, Roozenbeek B, Donkel SJ, van der Lugt A, et al. Association of NETs Markers with Clinical and Radiological Outcomes in Patients with Acute Ischemic Stroke Undergoing Thrombectomy: Does Heparin Treatment Modify This?. Translational Stroke Research. 2025. doi:10.1007/s12975-025-01362-0
BibTeX
@article{Barakzie2025,
author = {Barakzie, Aarazo and van der Steen, Wouter and Jansen, A J Gerard and Roozenbeek, Bob and Donkel, Samantha J and van der Lugt, Aad and Lingsma, Hester and Dippel, Diederik W J and Cate, Hugo Ten and de Maat, Moniek P M and CONTRAST consortium, CONTRAST consortium},
title = {Association of NETs Markers with Clinical and Radiological Outcomes in Patients with Acute Ischemic Stroke Undergoing Thrombectomy: Does Heparin Treatment Modify This?},
journal = {Translational Stroke Research},
year = {2025},
doi = {10.1007/s12975-025-01362-0}
}
EUVIMED